19:44 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

Biogen, UCB report Phase IIb miss for lupus candidate dapirolizumab

Biogen Inc. (NASDAQ:BIIB) and UCB S.A. (Euronext:UCB) reported top-line data showing dapirolizumab pegol missed the primary endpoint in a Phase IIb trial to treat moderate to severe active systemic lupus erythematosus (SLE) in patients receiving...
20:50 , Oct 23, 2018 |  BC Extra  |  Company News

Biogen halts vixotrigine development in painful lumbosacral radiculopathy

Biogen Inc. (NASDAQ:BIIB) will halt development of vixotrigine (BIIB074) for a pain indication after a Phase IIb miss disclosed in the biotech's 3Q18 earnings. Biogen beat total revenue and earnings estimates for the quarter, with...
08:00 , Nov 11, 2013 |  BC Week In Review  |  Clinical News

Anti-CD40L Fab: Phase Ib started

UCB disclosed in its earnings for the 9 months ended Sept. 30 that it began a Phase Ib trial to evaluate CDP7657 in patients with SLE. Biogen Idec and UCB are co-developing CDP7657 to treat...
08:00 , Jan 2, 2012 |  BC Week In Review  |  Company News

Biogen Idec, UCB, ALS TDI deal

Under a research agreement with Biogen Idec and UCB, the not-for-profit institute will conduct preclinical testing of the companies' CDP7657 to treat amyotrophic lateral sclerosis (ALS). After completing the study of the antibody targeting CD40...
07:00 , Aug 29, 2011 |  BioCentury  |  Strategy

R&D reboot

Charged with a mandate to reinvigorate and streamline R&D and ensure investors see value for money spent, Biogen Idec Inc. 's new management has pruned the pipeline and instilled a new culture of intelligent risk...
08:00 , Jan 27, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Musculoskeletal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Osteoporosis CD40 ligand (CD40LG; CD40L; CD154) Mouse studies suggest that inhibiting CD40L could help treat postmenopausal osteoporosis. In a mouse model of postmenopausal osteoporosis,...
08:00 , Nov 22, 2010 |  BioCentury  |  Regulation

Mild Was Enough

Leading up to last week's advisory committee meeting to discuss a BLA for lupus candidate Benlysta belimumab from Human Genome Sciences Inc. , the outcome hardly looked like a slam dunk. Based on a pair...
07:00 , May 10, 2010 |  BC Week In Review  |  Clinical News

Anti-CD40L Fab: Phase I started

UCB disclosed that it began a double-blind, placebo-controlled, dose-escalation Phase I trial to evaluate single doses of CDP7657 in healthy volunteers and SLE patients. The company is co-developing the agent with Biogen Idec. Biogen Idec...